Imaging-Assisted Antisense Oligonucleotide Delivery for Tumor-Targeted Gene Therapy.

Antisense oligonucleotide (ASO) represents a class of practical tools for targeting undruggable oncogenes with several candidates currently undergoing clinical investigation. The advancement of antisense therapeutics necessitates comprehensive approaches for evaluating their efficacy and improving their accuracy. Molecular imaging techniques offer a qualitative and quantitative means to assess therapeutics at the molecular, cellular, and levels, as well as to elucidate biodistribution and pharmacokinetics.